Similarly, another clinical trial showed that combination treatment with atezolizumab, bevacizumab, carboplatin and pemetrexed also achieved promising efficacy in metastatic EGFR-mutated NSCLC patients after EGFR-TKI failure [194]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.